AlphAIalphai — Financial news for AI agents
finanznachrichten.deJUN 193 min read$SOPH

SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares

SOPHiA GENETICS (Nasdaq: SOPH) said it closed an underwritten public offering after oversubscribed demand. The company sold 12,104,900 ordinary shares at $4.75 each, and underwriters fully exercised their option to buy an additional 1,578,900 shares. Gross proceeds were $57.5 million. TD Cowen led; Guggenheim, BTIG and Craig-Hallum also managed.

Original reporting
finanznachrichten.de
Published Jun 19, 2026, 12:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 19, 2026, 1:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$SOPH
Neutral
medium confidence
Mentioned
$SOPH
Relevance
6/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$SOPHNeutralMed
01

Why it matters

Closing details (gross proceeds, share count, and option exercise) confirm the financing is completed at a fixed public price, creating an identifiable dilution/overhang profile for SOPH.

02

Market read

Traders can update SOPH’s near-term supply/dilution expectations based on the final share issuance and offering completion.

03

What to watch

The article omits the stated use of proceeds and any expected timeline for deploying capital, which can be the key driver of whether dilution is viewed as value-accretive.

Relevance 6/10Novelty 7/10Timing: today/after-hours as the offering closing is announced

Background

SOPHiA GENETICS announced and then closed an underwritten public offering under an effective Form F-3 registration statement.

Company-level read

Ticker impact

$SOPHNeutralMedium confidence
Context

SOPHiA GENETICS closed a $57.5M underwritten public offering and fully exercised the underwriters’ option for 1,578,900 additional shares at $4.75.

Expected impact

Near-term downside risk from dilution/overhang, partially offset by strong investor demand for the deal.

Evidence & confidence

The article provides concrete deal size, pricing ($4.75), and share quantities, but no stated use of proceeds or guidance impact, limiting conviction on magnitude/direction.

Market effects

Sector

Adds to the broader biotech/healthcare-tech financing backdrop where AI/precision-medicine names may access capital via equity raises.

Regional

Limited; this is a Nasdaq-listed US equity financing with no Switzerland listing impact beyond offering mechanics.

Global

Low; the news is company-specific and does not indicate sector-wide regulatory or demand shifts.

Counterpoint

What could challenge this read

Oversubscription can signal the market is willing to fund the story despite dilution, reducing the probability of a sustained selloff.

Key entities

  • company
    SOPHiA GENETICS

    Nasdaq-listed AI-driven precision medicine company that closed a $57.5M public offering at $4.75/share.

  • financial_advisor
    TD Cowen

    Lead book-running manager for the offering.

  • financial_advisor
    Guggenheim Securities

    Book-running manager for the offering.

Read at source← All news

Related articles

AUG 11
$SOPHMedAI 8/10

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

SOPHiA GENETICS SA (SOPH) reported Q2 2026 revenue of $23.3 million, up 27%, and an adjusted EBITDA loss of $8.8 million. Platform analysis volume rose 22% to 115,000 patient analyses. Management raised full-year revenue guidance to $94 million to $96 million and reaffirmed adjusted EBITDA loss of $29 million to $32 million, citing U.S. in-house testing demand and biopharma growth.

fool.com6 min
AUG 4
$SOPHHighAI 9/10

SOPHiA GENETICS Reports Second Quarter 2026 Results

SOPHiA GENETICS (Nasdaq: SOPH) reported Q2 2026 revenue of $23.3 million, up 27% year over year, with gross margin of 64.6% reported and 72.1% adjusted. Net loss was $22.4 million and adjusted EBITDA loss was $8.8 million, improving 27%. The company raised 2026 revenue guidance to $94-$96 million and signed AstraZeneca companion diagnostic programs.

prnewswire.com6 min
AUG 4
$SOPHMed

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

SOPHiA GENETICS (NASDAQ: SOPH) said it entered a multi-year collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision oncology therapies. SOPHiA will advance its Solid Tumor decentralized CDx and develop a Hematological Oncology application for blood cancer. The programs aim to support commercialization of AstraZeneca therapies.

finanznachrichten.de4 min
AUG 28
$MAIRMedAI 8/10

Billionaire Tycoon Ernesto Bertarelli Buys $219 Million in Madison Air Solutions Shares. What Does This Mean for Investors?

Billionaire Ernesto Bertarelli indirectly purchased 8.8 million shares of Madison Air Solutions (MAIR) at $24.97 per share, totaling $219 million. The acquisition was made through K.C. Armada, LP, bringing his indirect ownership to 11% of the company. MAIR's stock closed at $28.51, a 14% premium over the purchase price. The company has a market cap of $14.3 billion and expects 18% revenue growth this fiscal year.

fool.com2 min
AUG 28
$STXMed

Moody’s upgrades Seagate Data rating on AI demand strength

Moody's upgraded Seagate Data's corporate family rating to Ba1 from Ba2, citing AI-driven demand for high-capacity HDDs. The agency expects revenues to grow over 30% annually, reaching $20B, and debt to EBITDA to fall below 0.5x. Seagate faces risks from revenue concentration and pricing pressures. The company had $1.7B in cash and access to a $1.3B credit facility as of July 2026.

investing.com2 min